ecrin-mdr-crcClinical2016IPD Sharing (as of February 2023): NoRenal Cell Carcinoma (RCC)Colorectal Cancer (CRC)Lung CancerNSCLCUC (Urothelial Cancer)Gastric CancerHead and Neck CancerCarcinoma, Renal CellMesotheliomaBladder CancerMetastatic CancerSolid TumorsRenal Cell Carcinoma (rcc)Colorectal Cancer (crc)Lung CancerNsclcGastric CancerCarcinoma, Renal CellMesotheliomaBladder CancerHead And Neck CancerMetastatic CancerUc (urothelial Cancer)Solid TumorsInterventionalhttps://newmdr.ecrin.org/Study/2225246NetherlandsUnited StatesItalySpain9Tumor MetabolismImmune TherapyProgrammed cell death protein-1 (PD-1) inhibitorImmuno-OncologySCCHNArginaseGEJPembrolizumabRCCProgrammed death ligand 1 (PD-L1) inhibitorCheckpoint InhibitorsArginase InhibitorMELINCB001158 (CB-1158)ECRIN MDRCompletedfalseArginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsThis study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.2016-09-152225246NCT02903914